DUBLIN (Reuters) - Biogen Idec is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug. Irish drugmaker Elan, which has co-marketed the drug with the larger U.S. company for 12 years, said it would receive a royalty of 12 percent of Tysabri global net sales for the first 12 months after the restructuring closes. ... Courtesy of Yahoo News
No comments:
Post a Comment